Verve Therapeutics, Inc. (VERV)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Verve Therapeutics, Inc. (VERV)
Go deeper and ask any question about VERV
Company Performance
Current Price
as of Sep 13, 2024$5.50
P/E Ratio
N/A
Market Cap
$465.43M
Description
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.
Metrics
Overview
- HQBoston, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerVERV
- Price$5.5-2.65%
Trading Information
- Market Cap$465.43M
- Float73.82%
- Average Daily Volume (1m)1,595,003
- Average Daily Volume (3m)1,461,956
- EPS-$2.60
Company
- Revenue$20.65M
- Rev Growth (1yr)219.73%
- Net Income-$49.81M
- Gross Margin75.09%
- EBITDA Margin-854.33%
- EBITDA-$57.17M
- EV-$92.45M
- EV/Revenue-4.48
- P/EN/A
- P/S22.44
Documents
SEC Filings
Factset Street Account